Shu-Fang Hsu Schmitz
Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
Lee C, Ashton-Key M, Cogliatti S, Rondeau S, Schmitz S, Ghielmini M, Cragg M, Johnson P. Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98). Br J Haematol 2014; 168:145-8.
Aug 21, 2014Expression of the inhibitory Fc gamma receptor IIB (FCGR2B, CD32B) on follicular lymphoma cells lowers the response rate to rituximab monotherapy (SAKK 35/98)
Aug 21, 2014Br J Haematol 2014; 168:145-8
Lee Chern Siang, Ashton-Key Margaret, Cogliatti Sergio B., Rondeau Stephanie, Schmitz Shu-Fang Hsu, Ghielmini Michele, Cragg Mark S, Johnson Peter
Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Martinelli G, Zucca E, Dietrich P, Lohri A, Vorobiof D, Heizmann M, Stahel R, Stupp R, Okkinga E, Bassi S, Hess U, Cerny T, Utiger U, Schmitz S, Ghielmini M. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010; 28:4480-4.
Aug 9, 2010Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98
Aug 9, 2010J Clin Oncol 2010; 28:4480-4
Martinelli Giovanni, Zucca Emanuele, Dietrich Pierre-Yves, Lohri Andreas, Vorobiof Daniel, Heizmann Marc, Stahel Rolf, Stupp Roger, Okkinga Emmie, Bassi Simona, Hess Urs, Cerny Thomas, Utiger Urs, Schmitz Shu-Fang Hsu, Ghielmini Michele
Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
Strasser F, Demmer-Steingruber R, Böhme C, Schmitz S, Thürlimann B, Cerny T, Gillessen Sommer S. Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study. The Oncologist 2008; 13:337-46.
Mar 1, 2008Prevention of docetaxel- or paclitaxel-associated taste alterations in cancer patients with oral glutamine: a randomized, placebo-controlled, double-blind study
Mar 1, 2008The Oncologist 2008; 13:337-46
Strasser Florian, Demmer-Steingruber Ruth, Böhme Christel, Schmitz Shu-Fang Hsu, Thürlimann Beat, Cerny Thomas, Gillessen Sommer Silke
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
Feb 1, 2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Feb 1, 2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. Breast Cancer Res Treat 2004; 87:75-86.
Sep 1, 2004Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?
Sep 1, 2004Breast Cancer Res Treat 2004; 87:75-86
Sabbioni Marzio E E, Hürny Christoph, Goldhirsch Aron, Herrmann Richard, Perey Lucien, Bonnefoi Hervé, Thürlimann Beat, Gertsch Monica Castiglione, Schmitz Shu-Fang Hsu, Siegrist Hans-Peter, Bernhard Jürg, Swiss Group for Clinical Cancer Research (SAKK)
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
Jun 15, 2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Jun 15, 2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas
Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Bertoni F, Cotter F, Cavalli F, Zucca E, Auer R, Jones C, Baldini L, Ponzoni M, Bertolini F, Pichert G, Fey M, Cerny T, Ghielmini M, Schmitz S, Cogliatti S, Conconi A, Swiss Group for Clinical Cancer Research. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British journal of haematology 2004; 124:289-98.
Feb 1, 2004Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research
Feb 1, 2004British journal of haematology 2004; 124:289-98
Bertoni Francesco, Cotter Finbarr E, Cavalli Franco, Zucca Emanuele, Auer Rebecca, Jones Chris, Baldini Luca, Ponzoni Maurilio, Bertolini Francesco, Pichert Gabriella, Fey Martin, Cerny Thomas, Ghielmini Michele, Schmitz Shu-Fang Hsu, Cogliatti Sergio B, Conconi Annarita, Swiss Group for Clinical Cancer Research